Photocure announces regulatory approval of Hexvix in Chile
Oslo, Norway, August 16, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that the Marketing Authorization for Hexvix[®] in Chile has been granted. Photocure’s partner and exclusive distributor, Genotests SpA, received the official regulatory approval by the Instituto de Salud Pública de Chile on August 12th.Now that the product is approved, Genotests will prepare for the commercialization. In August 2020, Photocure entered into an agreement with Genotests, a privately held company specializing in the marketing of genetic tests for cancer and targeting cancer